Sensyne Health FY revenues expected to be 'slightly ahead' of guidance
Sensyne Health
0.35p
16:50 17/06/22
Clinical AI technology group Sensyne Health said on Thursday that full-year revenues were expected to be "slightly ahead" of guidance.
FTSE AIM All-Share
753.12
16:50 25/04/24
Health Care Equipment & Services
11,737.57
17:09 25/04/24
Sensyne said sales for the year ended 30 April were projected to come in at £2.1m, a marked improvement on the £136,000 recorded in 2019 as a result of solid momentum in the second half.
The AIM-listed group stated that with the Covid-19 pandemic "rapidly" accelerating the adoption of digital technologies in healthcare systems around the world, the group was seeing increasing demand for its products and technology as healthcare systems and the biopharmaceutical industry as a whole adapts to the current situation.
Chief executive Paul Drayson said: "Sensyne has adapted well to the changing environment brought on by Covid-19, is performing strongly and, whilst remaining prudent in light of the coronavirus pandemic, is well placed to deliver strong revenue growth during 2020/21."
Elsewhere, Sensyne announced that Professor Bruce Keogh had agreed to become its permanent chairman after having taken on the role on an interim basis in December 2019.
As of 1035 BST, Sensyne shares were down 2.39% at 44.90p.